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Abstract
Background: Cerebral ischemia from middle cerebral artery wall (MCA) occlusion results in increased expression of
cerebrovascular endothelin and angiotensin receptors and activation of the mitogen-activated protein kinase
(MAPK) pathway, as well as reduced local cerebral blood flow and increased levels of pro-inflammatory mediators
in the infarct region. In this study, we hypothesised that inhibition of the cerebrovascular inflammatory reaction
with a specific MEK1/2 inhibitor (U0126) to block transcription or a combined receptor blockade would reduce
infarct size and improve neurological score.
Methods: Rats were subjected to a 2-hours middle cerebral artery occlusion (MCAO) followed by reperfusion for
48 hours. Two groups of treated animals were studied; (i) one group received intraperitoneal administration of a
specific MEK1/2 inhibitor (U0126) starting at 0, 6, or 12 hours after the occlusion, and (ii) a second group received
two specific receptor antagonists (a combination of the angiotensin AT1 receptor inhibitor Candesartan and the
endothelin ETA receptor antagonist ZD1611), given immediately after occlusion. The middle cerebral arteries,
microvessels and brain tissue were harvested; and the expressions of tumor necrosis factor-a (TNF-a), interleukin-
1ß (IL-1ß), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) and phosphorylated ERK1/2, p38 and JNK were
analysed using immunohistochemistry.
Results: We observed an infarct volume of 25 ± 2% of total brain volume, and reduced neurological function 2
days after MCAO followed by 48 hours of recirculation. Immunohistochemistry revealed enhanced expression of
TNF-a, IL-1ß, IL-6 and iNOS, as well as elevated levels of phosphorylated ERK1/2 in smooth muscle cells of ischemic
MCA and in associated intracerebral microvessels. U0126, given intraperitoneal at zero or 6 hours after the ischemic
event, but not at 12 hours, reduced the infarct volume (11.7 ± 2% and 15 ± 3%, respectively), normalized pERK1/2,
and prevented elevation of the expressions of TNF-a IL-1ß, IL-6 and iNOS. Combined inhibition of angiotensin AT1
and endothelin ETA receptors decreased the volume of brain damaged (12.3 ± 3; P < 0.05) but only slightly
reduced MCAO-induced enhanced expression of iNOS and cytokines
Conclusion: The present study shows elevated microvascular expression of TNF-a, IL-1ß, IL-6 and iNOS following
focal ischemia, and shows that this expression is transcriptionally regulated via the MEK/ERK pathway.
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Focal cerebral ischemia is a result of reduced cerebral
blood flow to a discrete region of the brain, and this initi-
ates a complex process that includes release of excitatory
neurotransmitters and activation of apoptotic pathways.
Even though regional cerebral blood flow may be
restored to near-normal values after 2 hours of middle
cerebral artery occlusion (MCAO) by release of the block
and consequent reperfusion [1], a cerebral infarct invol-
ving about 25% of total brain volume occurs consistently
[2]. Some manifestations of the ischemic damage are
break-down of the blood-brain barrier, activation of
inflammatory cascades, and disruption of basement
membranes and extracellular matrix via cytokine-induced
alterations in the expression of metalloproteinases [3].
Ischemia initiates a complex process in which inflam-
mation contributes to stroke-related brain injury. This is
evident in the systemic circulation as neutrophilia, lym-
phocytopenia and increased levels of monocytes [4].
There is an early accumulation of neutrophils in the
brain, and transmigration of adhesion molecules which
are associated with cytokine signaling [5]. In stroke-
induced brain injury cytokines such as tumor necrosis
factor-a (TNF-a), interleukin-1ß (IL-1ß), interleukin-6
(IL-6), and inducible nitric oxide synthase (iNOS), are
produced by a variety of activated cell types; endothelial
cells, microglia, neurons, platelets, monocytes, macro-
phages and fibroblasts [5]. The pattern of cytokine
inflammation response differs depending on stroke type
and localization. Even though regional cerebral blood
flow may be restored to near normal values after
MCAO through reperfusion [1], a reproducible cerebral
infarct occurs [2]. The ischemic region consists of two
p a r t s :t h ei s c h e m i cc o r ea n dt h ep e n u m b r a ,b o t ho f
which are recognized in clinical practice. Activation of
pro-inflammatory cytokines and iNOS in vessel walls
after cerebral ischemia may facilitate this process. Thus,
neuroinflammation is in principle a defence mechanism
designed to neutralize an insult and to restore structure
and function of the brain after an insult. Basically, neu-
roinflammation can be viewed as a protective mechan-
ism that isolates the damaged brain tissue from
uninjured areas, destroys affected cells, and repairs the
extracellular matrix [6]. All cells in the brain participate
in these inflammatory responses, including microglia,
macrophages, astrocytes, neurons, and oligodendrocytes.
The main mediators of neuroinflammation are
glial cells, constituting 70% of the total cell population
in the central nervous system. Thus, microglial cells
show a rapid response involving cell migration, prolif-
eration, and release of cytokines, chemokines and
trophic factors. In addition, there is recruitment of poly-
morphonuclear leukocytes (PMN) from the circulation.
PMN migration involves chemotaxis, adhesion to
endothelial cells, penetration of tight junctions and
migration through the extracellular matrix [7]. A co-
ordinated program of inflammation and resolution initi-
ates in the first few hours after an inflammatory
response has begun [8]. In recent years glial cells have
received growing attention for their role in coupling
events between synaptic activity and glucose metabolism
[9,10].
In the nucleus, activation of NF-kB plays a key role
[11]; it promotes gene expression and mediates tran-
scription of many genes implicated in the inflammatory
response (e. g. TNF-a, IL-1ß, IL-6, iNOS, inter alia)
[12]. As outlined in many reviews the neuroinflamma-
tion process is complex and involves numerous path-
ways and molecules in the brain; however, relatively
little attention has been directed towards the role of cer-
ebrovascular smooth muscle cells (SMCs) in this process
following cerebral ischemia.
Therefore, we aimed to examine early changes in the
expression of inflammatory signals that are known to be
involved in cerebral ischemia; first; to show enhanced
expression of pro-inflammatory mediators (iNOS and
cytokines) after transient MCAO in cerebrovascular
SMCs, and second, to evaluate if a specific transcription
MEK/ERK1/2 inhibitor (U0126) could modify this
enhanced expression, and to compare this to a com-
bined inhibition of upregulated angiotensin AT1 and
endothelin ETA receptors.
Methods
Middle cerebral artery occlusion
A total of 30 male Wistar-Hanover rats (Møllegaard
Breeding Centre, Copenhagen, Denmark), each weighing
approximately 300-350 g, were obtained from Harlan,
Horst, Netherlands. The animals were housed under
controlled temperature and humidity with free access to
water and food and were divided in 6 groups comprising
both control and treatment groups (5 rats in each
group). The experimental procedures were approved by
the University Animal Ethics Committee (M43-07).
Anaesthesia was induced using 4.5% halothane in
N2O:O2 (70%:30%) and was maintained by inhalation of
1.5% halothane by mask. To confirm proper occlusion
of the right MCA, a laser-Doppler probe (Perimed, Jär-
fälla, Sweden) was fixed to the skull (1 mm posterior to
the bregma and 6 mm from the midline on the right
side) to measure regional cortical blood flow. A poly-
ethylene catheter was inserted into a tail artery to mea-
sure mean arterial blood pressure, pH, pO2,p C O 2,a n d
plasma glucose. A rectal temperature probe connected
to a homeothermal blanket was used to maintain body
temperature at 37°C during the procedure.
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induce transient MCAO [2]. Briefly, an incision was
made in the midline of the neck, and the right common,
external, and internal carotid arteries were exposed. The
common and external carotid arteries were permanently
ligated with sutures. A filament was inserted into the
internal carotid artery via an incision in the common
carotid artery and advanced until the rounded tip
reached the entrance to the right MCA. The resulting
occlusion was visualized by laser-Doppler as an abrupt
80-90% reduction in cerebral blood flow. After 2 h of
occlusion, the rat was re-anesthetized to allow withdra-
wal of the filament; reperfusion was verified by laser-
Doppler recording.
Treatments
Experimental treatment regimes were done using two
strategies; one to inhibit transcription using a specific
inhibitor of MEK/ERK signalling, and the second to
inhibit MCAO-induced upregulation of G-protein
c o u p l e dr e c e p t o r s .T h e r e f o r e ,t oi n h i b i tM E K 1 / 2 ,a n i -
mals were injected intraperitoneal with 30 mg/kg/day
of U0126 dissolved in dimethylsulfoxide (DMSO),
beginning at reperfusion (0 h), or at 6 h, 12 h, or 24 h
post-occlusion [13]. Rats in the control groups were
injected with equal volumes of DMSO. It is well-
known that U0126 passes the blood-brain barrier with
difficulty. Hence, we chose a rather large dose of
U0126 which was chosen on the basis of previous
experiments [14].
A second group of animals were given specific recep-
tor blockade by administration intraperitoneal of Cande-
sartan (0.05 mg/kg) and ZD1611 (3-(4-[3-(3-methoxy-5-
methylpyrazine-2-ylsulfonyl)-2-pyridyl]-2,2-dimethylpro-
panoic acid) (0.15 mg/kg) immediately after the occlu-
sion and 24 hours later [13]. This research direction is
based on our findings that AT1 and ETA receptors are
crucial for development of the infarct size in this model
of cerebral ischemia. For the control group, rats were
injected with equal volume of DMSO.
Harvesting cerebral vessels and brain tissue
At 48 hours post-MCA occlusion, MCAO rats, MCAO
rats treated with either U0126 or Candesatan/ZD1611,
and their respective DMSO controls were anesthetized
and decapitated. The brains were removed and
immersed in ice-cold bicarbonate buffer solution of the
following composition (mM): NaCl 119, NaHCO3, 15,
KCl 4.6, MgCl2 1.2, NaH2PO4 1.2, CaCl2 1.5, and glu-
cose 5.5. The right and left MCAs and surrounding
brain tissue were dissected out using a dissection
m i c r o s c o p e ,s n a pf r o z e n ,a n ds t o r e da t- 8 0 ° Cf o r
immunohistochemical and confocal microscopy
analysis.
Neurological examination
The animals were subjected to a neurological examina-
tion prior to recirculation and immediately before they
were sacrificed (48 hours after MCAO), according to an
established scoring system [15,16] (Table 1).
Brain damage evaluation
The brains were sliced coronally in 2-mm-thick slices
and stained with 1% 2, 3, 5-triphenyltetrazolium chloride
(Sigma, St Louis, MO), dissolved in buffer solution at 37°
C, for 20 minutes. The extent of ischemic brain damage
was calculated as a percentage of the total brain volume
in the slices using the software program Brain Damage
Calculator 1.1 (MB Teknikkonsult, Lund, Sweden).
Immunofluorescence
For immunofluorescence analysis, the MCA and the sur-
rounding brain tissue were dissected out, placed into
Tissue TEK (Gibo, Invitrogen A/S, Taastrup, Denmark),
and frozen on dry ice; thereafter, they were sectioned
into 10-μm-thick slices. Cryostat sections of the arteries
and brain tissue were fixed for 10 minutes in ice-cold
acetone (-20°C) and then rehydrated in phosphate buffer
solution (PBS) containing 0.3% Triton X-100 for 15
minutes. The tissues were then permeabilized and
blocked for 1 hour in blocking solution containing PBS,
0.3% Triton X-100, 1% bovine serum albumin (BSA),
and 5% normal donkey serum, and then incubated over-
night at 4°C with the following primary antibodies: rab-
bit anti-rat iNOS (Abcam, ab15326), rabbit anti-rat IL-6
( A b c a m ,a b6 6 7 2 ) ,r a b b i ta nti-rat IL-1ß (Abcam,
ab9787) diluted 1:400, rabbit anti-rat TNF-a (18285;
IBL, Japan) diluted 1:20, rabbit anti-phospho p38 (Cell-
signalling, #9212), rabbit anti-phospho ERK1/2 MAPK
(Cellsignalling, #4376) diluted 1:50 and rabbit anti-phos-
pho SAPK/JNK (Cellsignalling, #.9251) diluted 1:100. All
primary antibodies were diluted in PBS containing 0.3%
Triton X-100, 1% BSA, and 2% normal donkey serum.
Sections were subsequently incubated for 1 hour at
room-temperature with secondary Cy™²-conjugated don-
key anti-rabbit (711-165-152; Jackson ImmunoResearch,
Europe Ltd., Suffolk, UK) diluted 1:200 in PBS contain-
ing 0.3% Triton X-100 and 1% BSA. The sections were
Table 1 Neurological status after MCA occulusion [15,16]
Score Interpretation
0 No visible deficits
1 Contralateral forelimb flexion, when held by tail
2 Decreased grip of contralateral forelimb
3 Spontaneous movement in all directions, but contralateral
circling if pulled by tail
4 Spontaneous contralateral circling
5 Death
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mafluore mounting medium (Beckman Coulter,
PNJM0752). Immunoreactivity was visualized and
photographed using a Nikon confocal microscope (EZ-
c1, German) at the appropriate wavelength. The same
procedure was used for the negative controls except that
primary antibodies were omitted.
Double immunofluorescence
Double immunofluorescence labelling was performed for
IL-1 ß, IL-6, iNOS, TNF-a, and phosphorylated ERK1/2
versus smooth muscle actin, expressed in the smooth
muscle cells. In addition to the antibodies described
above, we used mouse anti-rat smooth muscle actin
antibodies (SC-53015; Santa Cruz Biotechnology, Inc,
Santa Cruz, CA) diluted 1:200 in PBS containing 0.3%
Triton X-100, 1% BSA, and 2% normal donkey serum.
The secondary antibodies were Cy™²-conjugated donkey
anti-rabbit (Jackson ImmunoResearch) diluted 1:200 and
Texas Red-labeled donkey anti-mouse (Jackson Immu-
noResearch Europe) diluted 1:300 in PBS containing
0.3% Triton X-100 and 1% BSA. The antibodies were
detected at the appropriate wavelengths using a Nikon
confocal microscope (EZ-cl, Germany).
Image analysis and protein measurement for
immunoflourescence
Fluorescence intensity shown was related to expression of
protein levels in each sample and measured with a semi-
quantitative method. Fluorescence intensity was measured
using ImageJ software http://rsb.info.nih.gov/ij/. Measure-
ments were made in 4 to 6 different areas (located on the
clock at 0, 3, 6 and 9 h) for each tissue sample. The inves-
tigator was blinded to the treatment group of each sample,
the fluorescence intensity of each group was given as the
percentage change relative the control and the control
value was normalized to 100%. The mean value for each
was used for comparisons [13,17].
Calculations and statistical analyses
Data are expressed as mean ± standard error of the
mean (s.e.m). Statistical analyses were performed using
the nonparametric Kruskal-Wallis test with Dunn’sp o s t
hoc test. P-values less than 0.05 were considered signifi-
cant; “n” refers to the number of rats.
Results
In this study, we used a rat model of inducible cerebral
ischemia: animals were subjected to reversible MCAO
for 2 hours followed by reperfusion for 48 hours [2].
About 20 - 25% of animals in each group were excluded
from data analysis due to failure during the operational
procedure (the drop of cortical blood flow was too small
or technical problems). Immediately before MCAO, phy-
siological parameters (blood pressure, blood gases, tem-
perature, plasma glucose, and body weight) were
measured and there were no significant differences
between the different treatment groups (data not
shown) MCAO produced an occlusion visible by laser
Doppler flowmetry as an abrupt 80 - 90% reduction in
cerebral blood flow that normalized after removal of the
occluding thread. Following rapid sacrifice, tissues were
collected for immunocytochemistry and calculation of
infarct volume (25 ± 2% of total cerebrum in the
MCAO group; Figures 1 and 2a). Neurological evalua-
tions were performed just before animal sacrifice
(MCAO group, 4.0 ± 0.2 versus sham-operated animals
with no visible defects resulting in a score of 0; P <
0.05, Figure 2b).
Analysis of infarct volume and neurological examination
Previously, immunocytochemical and western blot ana-
lysis showed that MCAO with reperfusion causes activa-
tion of the MEK/ERK pathway and endothelin and
angiotensin receptor upregulation in cerebral vessels
associated with the ischemic region [14]; data from the
present study confirms this observation. Firstly, intrave-
nous administration of the MEK1/2 inhibitor U0126
[18] starting at 0 or 6 hours after MCAO and reperfu-
sion significantly reduced infarct volume (11.7 ± 2% and
15 ± 3%, respectively; P <0 . 0 5 ;F i g u r e s1a n d2 a )a n d
improved neurological assessment scores (2 ± 0.7 and
3.3 ± 0.7, respectively; P < 0.05, Figure 2b). When
U0126 treatment was initiated 12 hours after the start
Figure 1 Typical examples of coronal brain sections that show smaller ischemic areas in rats treated with combined Candesartan +
ZD1611, U0126 given at 0 and 6 hours after MCAO versus animals treated with vehicle (control). Treatment with U0126 given at 12
hours after MCAO did not decrease the ischemic area.
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Page 4 of 13Figure 2 a): Size of infarct volume (% of total brain volume) was significantly decreased in middle cerebral artery occlusion (MCAO)
animals treated with U0126 starting at 0 hours (11.7 ± 2%**) and 6 hours (14.6 ± 3%*) after MCAO as compared to the control group
(25 ± 2%). Treatment with U0126 starting at 12 hours after MCAO did not significant decrease the area of ischemia (20.3 ± 1%). Treatment with
combined inhibition of angiotensin AT1 (Candesartan) and endothelin ETA (ZD1611) receptors significantly decreased brain damage (12.3 ± 3).
Data are expressed as mean ± SEM; n = 4-7. *P < 0.05, ** < 0.01. b): Neurological scores in MCAO rats were significantly improved with
combined candesartan + ZD1611 and U0126 starting at 0 hours (2.6 ± 0.7% and 2 ± 0.7, respectively), compared to vehicle-treated rats (control).
Data are expressed as mean ± SEM; n = 6-7. *P < 0.05, ** P < 0.01.
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Page 5 of 13of reperfusion, there was no significant reduction in
infarct volume or neurological score when compared to
control animals (21 ± 2% and 3.8 ± 0.8%, respectively; P
< 0.05; Figures 1, 2a and 2b). Secondly, analysis of the
brains after staining with TTC revealed that the com-
bined treatment with Candesartan and ZD1611, injected
immediately after occlusion, resulted in significant
reduction in infarct volume (12.3 ± 3%; P < 0.05; Figures
1 and 2a) and improved neurological score at 48 h after
occlusion (2.6 ± 0.7%; P < 0.05; Figure 2b).
Expression and localization of iNOS, IL-1ß, IL-6 and TNF-a
Subsequently, we examined the MCA, cerebral micro-
vessels, and the surrounding brain tissue for changes
in protein expression of iNOS and pro-inflammatory
cytokines both in the ischemic region and in the con-
tralateral side at 48 hours after MCAO. There was
locally enhanced expression of iNOS, IL-16, IL-1ß and
TNF-a in smooth muscle cells in the ischemic region
both in the MCA leading to the stroke region and in
microvasculature walls (Figure 3, Tables 2 and 3).
Notably this enhanced expression was primarily seen
in smooth muscle cells, while a weak expression
occurred in endothelial cells for IL-6 (see below). The
surrounding brain tissue (neurons, astrocytes) was only
faintly stained as compared with that of the contralat-
eral side for iNOS, IL-6 and IL-1ß, but there was no
staining for TNF-a T h e r ew a sam a r k e de x p r e s s i o no f
iNOS, IL-1ß, IL-6 in vascular smooth muscle cells
from the ischemic region, localized to sarcoplasm and
leaving the nuclear region clear of expression (Figure
3). Quantification of this expression revealed signifi-
cant upregulation (Figure 3b, Tables 2 and 3) There
was no significant alteration in iNOS, IL-1ß, IL-6 and
TNF-a activity in brain tissue of the ischemic or of
contralateral regions (Table 4).
Inhibition AT1 and ETA receptors in vivo
In a previous study we observed that endothelin and
angiotensin receptors were upregulated in cerebrovascu-
lar smooth muscle cells [19,20]; here we tested the
hypothesis that these receptors might be involved in the
upregulation of cytokines and iNOS activity in vessels
walls. Thus, the administered combination of the angio-
tensin AT1 blocker Candesartan and the endothelin-1
ETA blocker ZD1611 systemically resulted in reduced
infarct size and in a better neurological score after
ischemic stroke in rat but not in enhanced receptor
expression induced by MCAO [13]. According to other
studies, both angiotensin II and endothelin-1 are pro-
inflammatory and these have previously been found to
be increased in cerebral ischemia. Here we found that
specific receptor antagonism reduces infarct volume and
neurological score (Figures 1, 2a and 2b), and in part
the elevated expression of IL-1 ß, IL-6, TNF-a and
iNOS (Figure 4 and Table 5).
Enhanced expression of MAPK and inhibition of MEK1
activity in vivo
We subsequently assessed if there were activation of
MAPK in the walls of the MCA, the microvessels and
surrounding brain tissue after MCAO. At baseline only
a faint expression was observed of pERK1/2 in the cere-
bral vessel walls. After MCAO, pERK1/2 activity in vas-
cular smooth muscle cells was significantly upregulated
in large cerebral arteries (185 ± 11%; P < 0.05) and in
microvessels (130 ± 10%; P < 0.05) (Figure 5) but not in
adjacent brain tissue (103 ± 4%; P > 0.05). U0126 treat-
ment initiated at time zero hours after initiation of
reperfusion normalized vascular pERK1/2 expression
(108 ± 5%, P < 0.05, Figure 5). Results from double
immunostaining with pERK1/2 and actin localized this
enhanced expression to smooth muscle cells (data not
shown). There was no or only very weak expression of
pp38 and pJNK in baseline samples and these were not
changed after MCAO and treatment with U0126 start-
ing at 0 hour (with injection) (110 ± 20%, 115 ± 17%,
respectively; P < 0.05; Figures 5a and 5b).
Because of the data from the MAPK analysis we
focused on the MEK/ERK1/2 pathway. Systemic admin-
istration of the potent MEK1-specific inhibitor U0126,
which blocks the enzymatic activity of MEK1, starting
either immediately after occlusion (0 hour) or at 6
hours after MCAO, effectively abolished the increase in
pERK1/2 activity in ischemic MCA and in cerebral
microvessels. There was no alteration in pERK1/2 activ-
ity in brain tissue of the ischemic or of contralateral
regions.
We observed that treatment with U0126 (with start at
0 or 6 hours) resulted in a decrease of the upregulated
activity of iNOS, IL-1ß, IL-6 and TNF-a in both the
MCA and the cerebral microvessels within the infarct
area (Figure 3, Tables 2 and 3). According to the co-
localization with actin in the smooth muscle cells, their
expression was localized to the vascular smooth muscle
cells, localized to the cytoplasm and leaving the nuclear
region clear of expression; for IL-6 we observed also
some staining of the endothelial cells (Figure 6). How-
ever, administration of U0126 with a start 12 hours after
MCAO did not significantly reduce the ischemia
induced expression of iNOS, IL-1ß, IL-6 or TNF-a in
the cerebral vessel smooth muscle cells (Figure 3, Tables
2 and 3).
Discussion
This is the first study to clearly demonstrate that
MCAO for 2 hours and reperfusion for 48 hours
resultes in significant upregulation of iNOS, IL-1ß, IL-6
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Page 6 of 13Figure 3 a): Confocal microscopy images of ischemic middle cerebral artery (MCA), cerebral microvessels (Mic.V), and surrounding
brain tissue (Brain) immunofluorescently labeled for iNOS (A-E), IL-6 (F-J), IL-1ß (K-O) and TNF-a (P-T). Images represent the vehicle
control group (A, P), MCAO plus vehicle group (B, Q), MCAO plus U0126 starting at 0 hours (C, R), 6 hours (D, S), or 12 hours (E, T). There were
significant increases in iNOS, IL-6, IL-1ß and TNF-a protein levels in the smooth muscle cell layer of ischemic vessels (MCA and Mic.V) as
compared with vessels from the vehicle control group. Treatment with U0126 starting at zero and 6 hours, but not 12 hours, after occlusion
prevented the increase in expression of these proteins. There was a slight increase in iNOS protein expression in ischemic brain tissue around
vessels as compared to control and U0126-treated brain tissue. Scale bar, 50 μm. b): Bar graphs showing semi-quantification of fluorescence
intensity for iNOS, IL-6, IL-1ß and TNF-a in MCA. There were significant increases in the expression of these proteins in MCAO animals as
compared to control animals; this increase was prevented with U0126 treatment starting at zero and 6 hours, but not 12 hours, post MCAO.
Data are presented as the mean percentage relative to control ± SEM.; n =5 .* P < 0.05, significant difference between control and treated at 12
h, **P < 0.01 significant difference between control groups and MCAO, #P < 0.05 and ##P < 0.01 significant difference between treatment
groups (0 h and 6 h) and MCAO groups.
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microvessels within the ischemic region. Furthermore,
our experiments revealed that this upregulation is prob-
ably a transcriptional event because it is associated with
a parallel upregulation of pERK1/2, and these changes
are all normalized by inhibition with U0126.
The specific MEK1 inhibitor U0126 has been shown
not to affect phosphorylation of p38 or JNK in cultured
neurons [21] or in cerebrovascular smooth muscle cells
in vivo [22]. Therefore, we can exclude the possibility
that U0126 acts via non-specific inhibition of pro-apop-
totic and pro-inflammatory mechanisms. U0126 has
been found to increase MEK1/2 phosphorylation in cor-
tical neurons, hence U0126 does not affect upstream
components of MEK1/2 [23]. Thus, it is reasonable to
assume that the neuroprotective effect of U0126 is the
result of inhibition of cerebrovascular MEK1 activity,
which is in agreement with reductions in the activity of
t h ed o w n s t r e a mM A P Kp E R K 1 / 2 .P r e s e n t l y ,M C A O
results in enhanced expression of pERK1/2 in smooth
muscle cells of ischemic MCA and in associated micro-
vessels (shown by co-localization with actin) but not in
surrounding brain tissue; U0126 blunts this activation in
parallel with a reduction in infarct volume and an
improved neurological score. The other MAPK p38 and
JNK were only mildly affected in vessel walls by MCAO;
however, as shown before there is enhanced pp38 and
pJNK in brain tissue subsequent to stroke that is mainly
localized to neurons and glial cells, and this occurs late
in the process [24].
Quite intriguing is our observation that inhibition of
this sequence of events correlates with inhibition of
iNOS, IL-1ß, IL-6 and TNF-a expression in the same
locale. Quantitative real-time PCR has demonstrated
enhanced mRNA expression of iNOS, IL-1ß and IL-6 at
24 hours after MCAO [22]. Our data suggest for the
first time that the enhanced expression of iNOS, IL-1ß,
IL-6 and TNF-a in cerebral ischemia is a transcription/
translational event in brain vessels, and points to a way
to modify their expression by MEK/ERK1/2 inhibition.
Previous work has indicated that MEK/ERK1/2
mechanisms play a crucial role in brain injury after
ischemia and reperfusion, with reductions in infarct size
resulting from inhibition of these mechanisms [21,25].
Table 2 Protein levels of iNOS, IL-6, IL-1ß and TNF-a in MCA after MCAO and treatment with U0126
Middle cerebral artery
Control MCAO MCAO + U0126-0 h MCAO + U0126-6 h MCAO + U0126-12 h
iNOS (%) ± s.e.m 100 ± 5 185 ± 16* 106 ± 9
# 116 ± 9
# 160 ± 9*
IL-6 (%) ± s.e.m 100 ± 6 177 ± 6** 113 ± 5
# 110 ± 5
# 137 ± 7
IL-1ß (%) ± s.e.m 100 ± 4 155 ± 4* 112 ± 8
# 109 ± 4
# 148 ± 16*
TNF-a ± s.e.m 100 ± 8.5 256 ± 24** 103 ± 8
## 132 ± 12
# 198 ± 7*
Values are expressed as percentage of control and given as mean ± s.e.m, n = 5-6, * P < 0, 05, ** P < 0, 01,
# P < 0, 05,
## P < 0, 01. * = significant difference
between control groups and MCAO or control and treated at 12 hours,
# = significant difference between MCAO and treatment groups (starting at 0 and 6 h).
Table 3 Protein levels of iNOS, IL-6, IL-1ß and TNF-a in microvessels after MCAO and treatment with U0126
Micro-vessels
Control MCAO MCAO + U0126-0 h MCAO + U0126-6 h MCAO + U0126-12 h
iNOS (%) ± s.e.m 100 ± 7.2 144 ± 1.0* 95 ± 10
# 109 ± 3.01 112 ± 8.4
IL-6 (%) ± s.e.m 100 ± 8.6 134 ± 4.4* 106 ± 7.8
# 101 ± 2.7
# 119 ± 3.6
IL-1ß (%) ± s.e.m 100 ± 3.1 125 ± 4.9* 113 ± 5.5
# 96 ± 2.4
# 122 ± 14.2
TNF-a ± s.e.m 100 ± 7.1 205 ± 12* 117 ± 11
# 117 ± 7.1
# 149 ± 9*
Values are expressed as percentage of control and given as mean ± s.e.m, n = 5-6,
*and
# P < 0, 05, * = significant difference between control groups and MCAO or control and treated at 12 hours,
# = significant difference between MCAO and
treatment groups (starting at 0 and 6 hours).
Table 4 Protein levels of iNOS, IL-6, IL-1ß and TNF-a in brain tissue after MCAO and treatment with U0126
Brain-tissue
Control MCAO MCAO + U0126-0 h MCAO + U0126-6 h MCAO + U0126-12 h
iNOS (%) ± s.e.m 100 ± 7 112.8 ± 6 104 ± 3 100.2 ± 5 103 ± 9
IL-6 (%) ± s.e.m 100 ± 4 108 ± 3.4 94 ± 5 95 ± 3.7 102 ± 5.6
IL-1ß (%) ± s.e.m 100 ± 4.7 122 ± 8.6 100 ± 5 100 ± 3 111 ± 3.1
TNF-a ± s.e.m 100 ± 8 119 ± 14 117 ± 10 114 ± 7.6 122 ± 8.9
Values are expressed as percentage of control and given as mean ± s.e.m, n = 5-6,
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Page 8 of 13Figure 4 a): Sections from the middle cerebral artery (MCA), cerebral microvessels (Mic.V), and surrounding brain tissue (Brain)
showing iNOS, IL-6, IL-1ß and TNF-a immunoreactivity in the smooth muscle cell layer. A) iNOS; control, B) iNOS; MCAO, C) iNOS; MCAO
treated with AT1/ETA receptor inhibitor (candesartan + ZD1611), D) IL-6;control, E) IL-6; MCAO, F) IL-6; MCAO treated with candesartan + ZD1611,
G) IL-1 ß; control, H) IL-1 ß; MCAO, I) IL-1 ß; MCAO treated with candesartan + ZD1611, J) TNF-a; control, K) TNFa; MCAO, L) TNFa, MCAO
treated with candesartan + ZD1611. There were increased expressions of iNOS, IL-6, IL-1ß and TNF-a protein levels in both middle cerebral artery
and cerebral microvessels after MCAO as compared to control groups. Treatment with AT1/ETA receptor inhibitors starting immediately after
induced MCAO diminished the increases in protein levels. There was no change in protein expression in ischemic brain tissue around vessels as
compared to control and treated brain tissue. Data were obtained with confocal microscopy. Scale bar 50 μm. b): Bar graphs showing
fluorescence intensity for iNOS, IL-6, IL-1ß and TNF-a in MCA. There were significant increases of the espressions of these proteins in MCAO
animals as compared to control animals. Treatment with AT1/ETA receptor inhibitors starting at 0 hours produced significant decreases in IL-6
and TNF-a protein levels and slight decreases in iNOS and IL-1ß protein levels. Data are presented as the mean percentage relative to control ±
SEM.; n =5 .* P < 0.05, significant difference between control group and MCAO, #P < 0.05, significant difference between MCAO and treated
group.
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Page 9 of 13Table 5 Protein levels of iNOS, IL-6, IL-1ß and TNF-a after MCAO and treatment with a combination of AT1/ETA
receptor antagonists
Middle cerebral artery Micro-vessels Brain tissue
Control MCAO Treated Control MCAO Treated Control MCAO Treated
iNOS(%) ± s.e.m 100 ± 5.4 168 ± 7* 139 ± 7.7 100 ± 11.5 146 ± 10* 118 ± 13 100 ± 5 118 ± 9 106 ± 6
IL-6(%) ± s.e.m 100 ± 3 180 ± 13* 104 ± 3
# 100 ± 4.9 146 ± 17* 103 ± 4 100 ± 8.9 109 ± 13 101 ± 12.2
IL-1ß(%) ± s.e.m 100 ± 5 146 ± 3* 117 ± 4.5 100 ± 5 117 ± 3.6 101 ± 3.8 100 ± 0.6 113 ± 4 102 ± 6.4
TNF-a ± s.e.m 100 ± 8 168 ± 8.7* 102 ± 12
# 100 ± 5 117 ± 3.6 101 ± 3.8 100 ± 0.6 113 ± 4 102 ± 6.4
Values are expressed as percentage of control and given as mean ± s.e.m, n = 3-4,
#,* P < 0, 05, * significant difference between control groups and MCAO,
# =
significant difference between MCAO and treatment groups.
Figure 5 a): Confocal microscopy images of ischemic middle cerebral artery (MCA) labeled for pERK 1/2 (A-C), pp38 (D-F) and pJNK
(G-I). There was increased pERK 1/2 in MCA of the MCAO group as compared with control, and treatment with U0126 at 0 hour prevented this
increase. Activation of pp38 and pJNK were not changed in the MCAO and treatment groups. Scale bar 50 μm. b): Bar graphs showing
fluorescence intensity for pERK1/2, pp38 and pJNK in MCA. Activation of pERK1/2 was significantly increased in MCAO as compared to control
group. Treatment with U0126 significantly decreased this activation. There was no alteration in protein expression of pp38 and pJNK in the
control, MCAO and treated groups. Data are presented as the mean percentage relative to control ± SEM.; n =5 .* P < 0.05, significant difference
between control group and MCAO, #P < 0.05, significant difference between MCAO and treated group.
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Page 10 of 13Figure 6 Double immunofluorescent staining for iNOS, IL-6, IL-1ß, TNF-a and actin in smooth muscle cells of the middle cerebral
artery after MCAO.( A-C) Photographs demonstrating the localization of iNOS and actin immunostaining, and their co-localization in smooth
muscle cells (yellow fluorescence in the merged picture). (D-F) IL-6 and actin immunostaining, and their co-localization in smooth muscle cells
(white arrows). (G-I) IL-1ß and actin immunostaining, and their co-localization (yellow fluorescence in the merged picture) in smooth muscle
cells. (J-L) TNF-a and actin immunostaining, and their co-localization in smooth muscle cells (yellow fluorescence in the merged picture).
Enhanced expressions of iNOS, IL-1ß and TNF-a proteins are located in smooth muscle cells while IL-6 is located in both smooth muscle (white
arrows) and endothelial cells (pink arrows). Scale bar, 50 μm.
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Page 11 of 13Here, we provide direct evidence for a possible explaina-
tion for some of the events that are related to the focal
pathology of cerebral ischemia. U0126 diminishes
pERK1/2 immunoreactivity in ischemic brain of mice
[21] and in the MCA of rats. In a mouse model employ-
ing MCAO for 3 hours followed by reperfusion for 24
hours, infarct volume was only affected if U0126 was
given at the time of MCAO [21]; this might, however,
be due to the use of too low a dosage. In a model using
permanent MCAO, pretreatment with U0126 was neces-
sary to inhibit pMEK1/2 and pERK1/2 expression in the
neuropil. Also the specificity of antagonisms revealed
that U0126 does not inhibit the cellular synthesis of
ERK1/2 but blocks ERK1/2 phosphorylation and activa-
tion of molecules such as transcription factor ELK-1. In
agreement with our observations, MEK1 inhibitors have
been found to not alter cortical blood flow in the first
few hours of administration [21,26], nor do they modify
the contractility of isolated cerebral arteries (Maddahi
and Edvinsson, unpublished data). Hence, MEK1 is not
acting on the cerebral circulation via a direct vasodilator
mechanism but, as we suggest, blunts receptor upregula-
tion [25]. We have here demonstrated yet another
important mechanism involved in cerebral ischemia,
neuroinflammation, and we have demonstrated that
U0126 blocks enhanced cerebrovascular expression of
iNOS, IL-1ß, IL-6 and TNF-a.
Following cerebral ischemia there is a pro-inflamma-
tory response, with infiltration of cells and generation of
interleukins and iNOS, often seen after a delay of about
24 hours following experimental focal ischemia. In this
study, we observe for the first time that, in conjunction
with MCAO and reperfusion for 48 hours, there is an
elevated expression of iNOS, IL-1ß, IL-6 and TNF-a in
MCA and in cerebral microvessels within the ischemic
region. This expression is localized to smooth muscle
cells (co-localization with actin). At a time point 24
hours after MCAO, real time-PCR has demonstrated
within vessel walls enhanced expression of mRNA for
IL-1ß and IL-6 but not for iNOS [22]. This supports
involvement of a transcriptional event. Wang and collea-
gues observed that the level of IL-1ß is increased in
ischemic regions after permanent MCAO in mice
[27,28] and [29]. This enhanced expression of IL-1ß
mRNA is inhibited by U0126 treatment. Interestingly,
protein expression in these smooth muscle cells appears
to be upregulated via de novo transcription involving the
MEK/ERK1/2 pathway since inhibition of pERK1/2
activity with MEK1 inhibitor markedly reduces their
expression.
Endothelin-1 and angiotensin II are involved in
inflammatory processes, in addition to their potent vaso-
motor effects; consequently direct receptor inhibition
m i g h tb eag o o dw a yt or e d u c ei n f a r c tv o l u m ea f t e r
MCAO. The use of specific endothelin [30] or angioten-
sin receptor antagonists [31] has been found to provide
some reduction in infarct size, but a combined receptor
blockade shows stronger effects due to combined upre-
gulation of several receptor subtypes [13]. However,
such combined treatment does not modify the upregula-
tion of the G-protein coupled receptors studied, but
blocks their effect and reduces infarct size. However,
while receptor antagonism does not change the upregu-
lation of pERK1/2 and iNOS levels, it does reduce the
expression of IL-1ß, IL-6 and TNF-a in vessel walls,
possibly via an anti-inflammatory effect. The back-
ground to the use of the present receptor blockade was
a series of studies on receptor regulation in cerebral
ischemia models which has revealed elevation of AT1,
ETA and ETB receptors [19,20] and [32] in MCA
smooth muscle cells. Our decision not to choose an ETB
receptor blocker was based on negative experimental
data [33], on the fact that upregulation of contractile
ETB receptors takes some time [34,35], and on the fact
that early treatment results only in blockade of vasodila-
tor ETB receptors (which may be of value during early
phases of stroke).
Conclusion
The use of MEK1 inhibition might be a way to obtain
anti-stroke efficiency since it targets several transcrip-
tional mechanisms activated by cerebral ischemia: (i)
receptor upregulation causing enhanced contractility,
and (ii) inflammatory gene activation, i.e., for iNOS, IL-
1ß, IL-6 and TNF-a. MEK1 inhibition, applied as late as
6 hours after the start of reperfusion, significantly
reduced infarct volume and, in parallel, reduced the
upregulation of contractile receptors, and reduced the
elevation of iNOS, IL-1ß, IL-6 and TNF-a in cerebral
vessel walls. The positive effects of a MEK1 inhibitor
might thus involve several mechanisms in MCA and in
brain microvasculature associated with the cerebral
ischemia.
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